- Home
- HLT vs ALNY Comparison
HLT vs ALNY Comparison
Compare HLT & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLT
- ALNY
- Stock Information
- Founded
- HLT 1919
- ALNY 2002
- Country
- HLT United States
- ALNY United States
- Employees
- HLT N/A
- ALNY N/A
- Industry
- HLT Hotels/Resorts
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- HLT Consumer Discretionary
- ALNY Health Care
- Exchange
- HLT Nasdaq
- ALNY Nasdaq
- Market Cap
- HLT 61.7B
- ALNY 60.7B
- IPO Year
- HLT 2013
- ALNY 2004
- Fundamental
- Price
- HLT $266.39
- ALNY $435.52
- Analyst Decision
- HLT Buy
- ALNY Strong Buy
- Analyst Count
- HLT 14
- ALNY 26
- Target Price
- HLT $275.21
- ALNY $484.08
- AVG Volume (30 Days)
- HLT 1.8M
- ALNY 1.2M
- Earning Date
- HLT 10-22-2025
- ALNY 10-30-2025
- Dividend Yield
- HLT 0.23%
- ALNY N/A
- EPS Growth
- HLT 48.63
- ALNY N/A
- EPS
- HLT 6.91
- ALNY 0.33
- Revenue
- HLT $4,870,000,000.00
- ALNY $3,210,070,000.00
- Revenue This Year
- HLT $7.84
- ALNY $65.55
- Revenue Next Year
- HLT $7.83
- ALNY $41.48
- P/E Ratio
- HLT $38.26
- ALNY $1,317.43
- Revenue Growth
- HLT 3.73
- ALNY 53.24
- 52 Week Low
- HLT $196.04
- ALNY $205.87
- 52 Week High
- HLT $279.81
- ALNY $495.55
- Technical
- Relative Strength Index (RSI)
- HLT 53.87
- ALNY 41.76
- Support Level
- HLT $253.54
- ALNY $417.00
- Resistance Level
- HLT $271.13
- ALNY $485.36
- Average True Range (ATR)
- HLT 6.04
- ALNY 18.11
- MACD
- HLT 0.16
- ALNY -5.61
- Stochastic Oscillator
- HLT 47.99
- ALNY 25.20
About HLT Hilton Worldwide Holdings Inc.
Hilton Worldwide Holdings operates 1.3 million rooms across its more than 20 brands serving the premium economy through luxury segments. Hampton and Hilton are the two largest brands, representing 27% and 18%, respectively, of the company's total rooms, as of Dec. 31, 2024. Recent brands launched over the last few years include Home2, Curio, Canopy, Spark, Tru, Tempo, and LivSmart, as well as a partnership with Small Luxury Hotels of the World and acquisitions of NoMad and Graduate Hotels. Managed and franchised hotels represent the vast majority of adjusted EBITDA, predominantly from the Americas.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.